274 results on '"Blumenschein, G R"'
Search Results
2. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
3. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
4. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
5. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
6. Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer
7. FAC + BCG as Adjuvant Therapy in Breast Cancer: An 8-Year Update
8. Adjuvant Therapy of Stage II, III Breast Cancer
9. Chemo Immunotherapy of Advanced Breast Cancer With BCG
10. Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease free interval and survival
11. Adjuvant Therapy of Stage II, III Breast Cancer
12. Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer
13. FAC + BCG as Adjuvant Therapy in Breast Cancer: An 8-Year Update
14. Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.
15. Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
16. Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial.
17. Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results.
18. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.
19. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.
20. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).
21. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.
22. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.
23. Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer.
24. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).
25. A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).
26. Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC)
27. Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results
28. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial
29. RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)—Association between EGFR gene copy number and patients’ outcome
30. A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results
31. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors
32. Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs)
33. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis
34. A phase I dose escalation study of pemetrexed in patients with advanced head and neck squamous cell cancer (HNSCC)
35. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history
36. Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib
37. Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin
38. Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer
39. The risk of distant metastases in patients with non-small cell lung cancer (NSCLC) with cytologically proven malignant pleural effusion, stage IIIB: A retrospective analysis
40. A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
41. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
42. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
43. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement.
44. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer.
45. Multimodal treatment of locoregionally advanced breast cancer.
46. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen.
47. Treatment for meningeal carcinomatosis in breast cancer.
48. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer.
49. Peptichemio versus melphalan (L-PAM) in advanced breast cancer.
50. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.